Stock Track | Embecta Corp. Plummets 5.99% as Revenue Guidance Cut Despite Q1 Earnings Beat

Stock Track

Feb 06, 2025

Embecta Corp.'s stock plunged 5.99% on Thursday's trading session, following the release of its fiscal Q1 2025 earnings report.

The medical device company reported adjusted earnings of $0.65 per share for the quarter ended December 31, exceeding analysts' expectations of $0.44. However, Embecta lowered its full-year 2025 revenue guidance to $1.08 billion to $1.09 billion, down from the previous range of $1.09 billion to $1.11 billion. This reduced outlook weighed on investor sentiment, leading to the stock's decline.

Despite the revenue guidance cut, Embecta maintained its adjusted earnings per share forecast for fiscal 2025 at $2.70 to $2.90, in line with analysts' estimates of $2.80. The company also reported a dividend of $0.15 for the quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1152634649"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152634649\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152634649?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152634649","market":"hk","top_or_hot":-1,"title":"Stock Track | Embecta Corp. Plummets 5.99% as Revenue Guidance Cut Despite Q1 Earnings Beat","media":"Stock Track","content":"<p>Embecta Corp.'s stock plunged 5.99% on Thursday's trading session, following the release of its fiscal Q1 2025 earnings report.</p>\n\n<p>The medical device company reported adjusted earnings of $0.65 per share for the quarter ended December 31, exceeding analysts' expectations of $0.44. However, Embecta lowered its full-year 2025 revenue guidance to $1.08 billion to $1.09 billion, down from the previous range of $1.09 billion to $1.11 billion. This reduced outlook weighed on investor sentiment, leading to the stock's decline.</p>\n\n<p>Despite the revenue guidance cut, Embecta maintained its adjusted earnings per share forecast for fiscal 2025 at $2.70 to $2.90, in line with analysts' estimates of $2.80. The company also reported a dividend of $0.15 for the quarter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Embecta Corp. Plummets 5.99% as Revenue Guidance Cut Despite Q1 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Embecta Corp. Plummets 5.99% as Revenue Guidance Cut Despite Q1 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-06 22:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Embecta Corp.'s stock plunged 5.99% on Thursday's trading session, following the release of its fiscal Q1 2025 earnings report.</p>\n\n<p>The medical device company reported adjusted earnings of $0.65 per share for the quarter ended December 31, exceeding analysts' expectations of $0.44. However, Embecta lowered its full-year 2025 revenue guidance to $1.08 billion to $1.09 billion, down from the previous range of $1.09 billion to $1.11 billion. This reduced outlook weighed on investor sentiment, leading to the stock's decline.</p>\n\n<p>Despite the revenue guidance cut, Embecta maintained its adjusted earnings per share forecast for fiscal 2025 at $2.70 to $2.90, in line with analysts' estimates of $2.80. The company also reported a dividend of $0.15 for the quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EMBC","symbol_name":"Embecta Corp.","start_time":0,"source_url":"","article_id":"1152634649","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152634649","pubTimestamp":1738852374,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Embecta Corp.'s stock plunged 5.99% on Thursday's trading session, following the release of its fiscal Q1 2025 earnings report.The medical device company reported adjusted earnings of $0.65 per share for the quarter ended December 31, exceeding analysts' expectations of $0.44. However, Embecta lowered its full-year 2025 revenue guidance to $1.08 billion to $1.09 billion, down from the previous range of $1.09 billion to $1.11 billion. This reduced outlook weighed on investor sentiment, leading to","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EMBC":"Embecta Corp."},"translate_title":"尽管第一季度盈利好于预期，但收入指引下调，Embecta Corp.股价暴跌5.99%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMBC":1},"content_text":"Embecta Corp.'s stock plunged 5.99% on Thursday's trading session, following the release of its fiscal Q1 2025 earnings report.\nThe medical device company reported adjusted earnings of $0.65 per share for the quarter ended December 31, exceeding analysts' expectations of $0.44. However, Embecta lowered its full-year 2025 revenue guidance to $1.08 billion to $1.09 billion, down from the previous range of $1.09 billion to $1.11 billion. This reduced outlook weighed on investor sentiment, leading to the stock's decline.\nDespite the revenue guidance cut, Embecta maintained its adjusted earnings per share forecast for fiscal 2025 at $2.70 to $2.90, in line with analysts' estimates of $2.80. The company also reported a dividend of $0.15 for the quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}